Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Illumina, Inc. et al v. BGI Genomics Co., Ltd et al
Case Number:
3:19-cv-03770
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 12, 2020
BGI Genomics Can Develop DNA Tech During Patent Appeal
Chinese genetics company BGI Genomics can continue developing its DNA sequencing products as it appeals the scope of a preliminary injunction that gave Illumina total control of the U.S. market for the technology, a California federal judge has ruled.
-
June 16, 2020
Illumina Wins Bid To Block BGI Genomics' DNA Product Sales
Illumina has scored a victory in its patent battle against Chinese genetics company BGI Genomics, with a California federal judge issuing a ban against BGI's DNA sequencing products, despite arguments that this would give Illumina total control over the U.S. market at a critical time.
-
May 11, 2020
Illumina Nears Win In Bid To Block BGI's DNA Product Sales
A California federal judge said Monday that he's inclined to grant Illumina's preliminary bid to block China-based BGI Genomics from selling DNA sequencing products accused of infringing its patents, while BGI argued that an injunction would give Illumina total control of DNA sequencing in the Unites States at a critical time.
-
February 05, 2020
Illumina Beats Claims Its Attys Deceived PTAB, Fed. Circ.
A California federal judge on Wednesday threw out Complete Genomics Inc.'s allegations that Illumina Inc.'s IP counsel engaged in inequitable conduct by misleading the Federal Circuit and the PTAB about prior art related to DNA sequencing technology patents.
-
January 15, 2020
BGI's Counterpunch Against Illumina Draws Mixed Reaction
A California federal judge overseeing Illumina's patent infringement suit against China-based BGI Genomics over DNA sequencing technology gave a mixed response to BGI's counterclaims at a hearing Wednesday, saying BGI's induced infringement claim had factual support while its inequitable conduct claim didn't.
- ← Previous
- 1
- 2
- Next →